KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $334.8 million.

  • Acadia Pharmaceuticals' Accumulated Expenses rose 3.07% to $334.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.8 million, marking a year-over-year increase of 3.07%. This contributed to the annual value of $378.7 million for FY2024, which is 59.97% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Accumulated Expenses stood at $334.8 million for Q3 2025, which was up 8.04% from $309.9 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Accumulated Expenses ranged from a high of $378.7 million in Q4 2024 and a low of $80.5 million during Q3 2021.
  • Its 3-year average for Accumulated Expenses is $279.3 million, with a median of $309.9 million in 2025.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first decreased by 8.93% in 2021, then surged by 109.69% in 2023.
  • Acadia Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $89.2 million in 2021, then grew by 26.56% to $112.9 million in 2022, then surged by 109.69% to $236.7 million in 2023, then surged by 59.97% to $378.7 million in 2024, then rose by 3.07% to $334.8 million in 2025.
  • Its Accumulated Expenses stands at $334.8 million for Q3 2025, versus $309.9 million for Q2 2025 and $284.4 million for Q1 2025.